
After egg collection or embryo transfer, many couples are asked to start a hormone medicine and keep taking it for days or weeks. That medicine is usually progesterone. Questions about progesterone after IVF come up often: why is it needed, when does it start, how long does it continue, and is a tablet, a vaginal preparation or an injection better? Indian guidance from the Federation of Obstetric and Gynaecological Societies of India (FOGSI) and European guidance from the European Society of Human Reproduction and Embryology (ESHRE) both treat luteal phase support with progesterone as a standard part of stimulated IVF and ICSI. This article explains those practice points in plain words. It is general information, not a personal prescription; your treating doctor chooses the product, route and dose for your cycle.
The short answer
Progesterone prepares and supports the lining of the womb so an embryo can implant and early pregnancy can continue. In stimulated IVF and ICSI, the body's own luteal-phase progesterone is often lower than in a natural cycle, so clinics routinely add progesterone. FOGSI key practice points (2024) recommend progesterone for luteal phase support after IVF/ICSI, starting from the day of oocyte retrieval or within 72 hours after. ESHRE's ovarian stimulation guideline (updated 2025) likewise recommends progesterone and advises starting it between the evening of oocyte retrieval and day 3 after retrieval. Support continues at least until the pregnancy test; many clinicians continue into early pregnancy until around the luteo-placental shift. Routes include oral (including dydrogesterone discussed in FOGSI), vaginal micronised progesterone, intramuscular and subcutaneous injections — the treating doctor decides which option suits you.
What is the luteal phase, and why does IVF need extra support?
The luteal phase is the part of the menstrual cycle that begins after ovulation and ends either with a period or with an established pregnancy. In a natural cycle, the corpus luteum (the shell left behind after the egg is released) produces progesterone. That hormone thickens and stabilises the endometrium, the lining of the uterus, so it is ready for implantation.
In IVF and ICSI, several steps change this picture. Ovarian stimulation grows many follicles at once. Medicines used to prevent a premature LH surge, and the trigger injection itself, can disrupt the natural corpus luteum. As a result, progesterone production in the luteal phase of a stimulated cycle is often inadequate for the endometrium. That is why luteal phase support (LPS) is used in nearly all stimulated ART cycles, as FOGSI's 2024 key practice points note.
It helps to separate two ideas that sound similar. Luteal phase deficiency (LPD) in a natural cycle is a separate clinical concept. The American Society for Reproductive Medicine (ASRM) 2021 committee opinion discusses diagnosis and treatment of LPD in that natural-cycle setting. Routine progesterone after IVF is different: it is planned support after stimulation and egg retrieval or after a programmed frozen transfer, not the same as treating a short natural luteal phase. Your doctor will explain which situation applies to you.
Why progesterone after IVF (or embryo transfer)
Progesterone's job after IVF or embryo transfer is to support the endometrium while the embryo tries to implant and, if pregnancy begins, until the placenta takes over enough hormone production. Without enough progesterone, the lining may not stay receptive.
FOGSI's 2024 key practice points state that progesterone is recommended for LPS following IVF/ICSI. ESHRE's ovarian stimulation guideline for IVF/ICSI (updated 2025) also recommends progesterone for luteal support after IVF/ICSI (strong recommendation). Both documents treat progesterone as the usual backbone of LPS. Other agents, such as hCG, have been used for luteal support in the past, but guidance links hCG LPS with a higher risk of OHSS compared with progesterone, which is why progesterone is preferred for routine use.
You can see where this step sits in the wider pathway in our step-by-step IVF process guide and on our fertility treatment overview (IVF, ICSI, IUI, follicular monitoring and related procedures).
When progesterone usually starts
Timing matters. Starting progesterone too early (before oocyte retrieval) has been linked in older studies with poorer implantation, likely because the endometrium advances out of sync with the embryo. Starting too late may leave the lining under-supported.
FOGSI practice points advise that progesterone should be started from the day of oocyte retrieval or within 72 hours after oocyte retrieval. ESHRE recommends initiating LPS with progesterone in the window between the evening of the day of oocyte retrieval and day 3 after oocyte retrieval. In day-to-day practice, your clinic will tell you the exact start time for your protocol.
Frozen embryo transfer (HRT-FET) timing
In a hormone-replacement (programmed) frozen embryo transfer, there is no corpus luteum, so progesterone timing is tied to endometrial preparation rather than to egg retrieval. FOGSI practice points state that in HRT-frozen ET cycles, progesterone should be started after adequate endometrial preparation, with endometrial thickness often discussed in the literature as at least greater than 8 mm. That figure is from published practice points, not a MOM IVF clinic protocol; your doctor sets thresholds and start dates for your cycle. FOGSI also summarises common timing for cleavage-stage and blastocyst transfers after progesterone begins, again as guidance literature rather than a fixed clinic rule.
If embryos from an earlier cycle are stored for later use, our page on embryo preservation explains freezing and storage in general terms.
How long support usually continues
How long to take progesterone after embryo transfer is one of the most common questions. Guidance and everyday practice are not identical, so it helps to know both.
- At least until the pregnancy test. FOGSI practice points say LPS should be continued until a positive pregnancy test is confirmed. ESHRE recommends continuing progesterone at least until the day of the pregnancy test (good practice point).
- Often into early pregnancy. FOGSI notes that many clinicians continue LPS until about the 10th week of gestation, around the time of the luteo-placental shift, when the placenta produces enough progesterone on its own. That is described as common clinical practice (expert-level practice point), not a promise about outcomes.
- Early stop vs longer support. Meta-analyses cited in FOGSI discuss early cessation versus continued progesterone after a positive test; results on live birth and miscarriage have not shown a clear difference in every analysis. Your doctor will explain the plan used for your cycle and when to stop.
Never stop or change the dose on your own because of spotting, breast tenderness or other side effects without speaking to the clinic first. The schedule is part of the treatment plan.
Common ways progesterone is given
Progesterone for LPS can be given by several routes. FOGSI states that the route should be individualised according to patient preference, efficacy and side effects. ESHRE accepts non-oral natural progesterone routes (intramuscular, subcutaneous or vaginal) and also discusses oral dydrogesterone as an option. No single route is right for everyone, and this article does not recommend a brand or tell you which route to choose; that decision belongs to your treating doctor.
| Route | What it usually involves | Tolerability notes often discussed |
|---|---|---|
| Oral (including dydrogesterone) | Tablets taken by mouth on a schedule set by the doctor | FOGSI discusses oral dydrogesterone as a potential LPS option and notes patient satisfaction and tolerability in published comparisons with vaginal micronised progesterone. Dose and product are chosen by the doctor. |
| Vaginal micronised progesterone | Capsules, gel or pessaries placed in the vagina | Common LPS route. Some people report discharge or local irritation; compliance can be an issue for that reason. |
| Intramuscular (IM) injection | Injection into a muscle, often the buttock | Effective in studies; injection-site pain and irritation are more often reported than with subcutaneous use. |
| Subcutaneous injection | Injection under the skin | Guidance and reviews discuss similar efficacy to vaginal progesterone for LPS in studied settings, with generally fewer injection-site reactions than IM. |
FOGSI practice points also discuss combining oral dydrogesterone with vaginal micronised progesterone in some FET settings. Whether combination support is used, and at what dose, is an individual clinical decision for your doctor.
Fresh cycles, frozen transfers and OHSS caution
Luteal support is not identical in every cycle type.
- Fresh IVF/ICSI with embryo transfer. Progesterone LPS is routine after retrieval. If a GnRH agonist trigger was used instead of hCG (often when OHSS risk is a concern), the luteal phase may need a carefully planned, sometimes modified, support regimen. FOGSI mentions that individualised LPS may include low-dose hCG in selected agonist-trigger fresh-transfer settings; that is a specialist decision, not a default for every patient.
- Freeze-all / deferred transfer. When all embryos are frozen and transfer is delayed, early pregnancy hCG is avoided in that stimulated cycle, which lowers the risk of late OHSS. LPS for the later frozen transfer follows the FET protocol.
- hCG as luteal support. Using hCG for LPS is linked with a higher risk of OHSS than using progesterone. That is a main reason guidance prefers progesterone for routine LPS.
- HRT-FET. Because there is no corpus luteum, progesterone (and usually oestrogen) is essential until the placenta takes over or the cycle is stopped after a negative test.
If you have been told you are at higher risk of OHSS, ask how the trigger choice and the luteal plan work together. Do not add extra hCG products on your own.
Practical tips and questions to ask
A few practical points help most people stick to the plan:
- Take or apply the medicine at the times written on your sheet; set phone reminders if needed.
- If using vaginal progesterone, ask the clinic about timing around intercourse, swimming or using other vaginal products.
- Report severe pain, breathlessness, rapid tummy swelling, vomiting or very little urine promptly; those can be OHSS warning signs after a stimulated cycle, not "normal" progesterone side effects.
- Keep taking support until the clinic tells you to stop, including after a positive test if that is the plan.
- Bring a list of all medicines and supplements to each visit so interactions and duplicates can be checked.
Useful questions for your doctor or nurse:
- When exactly should I start progesterone in this cycle, and at what clock times?
- Which route are you recommending for me, and why does it suit my protocol?
- How long will I continue after a positive pregnancy test, and what is the stop date if the test is negative?
- What side effects should I expect, and which ones mean I should call the same day?
- If I miss a dose, what should I do?
- Does my fresh-cycle trigger (hCG or agonist) change the luteal plan?
For appointment timings and how monitoring fits around medicines, see our fertility treatment page or book a consultation.
Talk to us
If you have questions about medicines in your IVF or frozen-transfer plan, our team can explain the schedule your doctor has prescribed.
To book a consultation, call +91 98986 83636 (Monday to Saturday, 11 AM to 3 PM) or use the appointment form.
MOM IVF Fertility & Research Center Pvt. Ltd., 12-2-710, 1st & 2nd Floors, Beside Premier Hospital, Nanal Nagar X Roads, Mehdipatnam, Hyderabad, Telangana 500028.
Sources
- FOGSI. Key Practice Points: The current practice of luteal phase support (2024 PDF).
- ESHRE. Ovarian stimulation for IVF/ICSI guideline (updated 2025). Full text: Human Reproduction update PDF.
- Practice Committees of the ASRM and the Society for Reproductive Endocrinology and Infertility. Diagnosis and treatment of luteal phase deficiency: a committee opinion (2021) — natural-cycle LPD context; distinct from routine IVF luteal support.
This article is general health information and is not a substitute for a consultation. Treatment decisions depend on individual tests and medical history. Research figures quoted here come from published studies and are not MOM IVF results.


